Dare Bioscience Inc. (DARE) Company Long-Term Loans and Borrowings

Dare Bioscience, Inc. (DARE) is a biotech developer creating advanced gynecological products with a focus on local component delivery. This price chart confirms the asset's dynamics, where long-term debt stands at 0.00. Dare Bioscience, Inc. (DARE) generates revenue through the sale of contraceptives and menopause therapies in collaboration with specialized clinics. The company protects its market position through patent law and a partnership with Organon, which ensures a steady influx of consumers.

DARE Dare Bioscience, Inc.: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Dare Bioscience Inc. - analytical breakdowns and key metrics (DARE)

- price and consensus price forecast:

Stock Price darebioscience.com|DARE - Price Target Chart

- market capitalization data:

Market Value Daré Bioscience|DARE - Total Company Value

- book capitalization data:

Accounting Value per Share Daré Bioscience|DARE - Book Capitalization|Market Capitalization to Book Value Ratio darebioscience.com|DARE - Cumulative Company Assets

- debt and liquidity data:

Fundamental valuation:darebioscience.com (DARE)

Mass-produced product of Dare Bioscience, Inc.

The dynamics of liabilities with a maturity of more than one year directly reflect the ability of cash flows to service the debt load, capturing the total volume of loans and bonds. For Dare Bioscience, Inc. (DARE), which invests in clinical development through strategic alliances, analyzing the company's long-term debt chart allows for the differentiation of financial degradation risks from targeted funding for expansion within the women's healthcare sector.

Competitor analysis for Dare Bioscience, Inc.

organon.com - Company Long-Term Debts|Company Long-Term Debt TherapeuticsMD Corp (TXMD)|PTN: Company Long-Term Loans and Borrowings